Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.

People living with HIV (PLWH) with low CD4 T-cell counts may be at a higher risk for severe coronavirus disease 2019 (COVID-19) outcomes and in need of efficient vaccination. The World Health Organization (WHO) now recommends prioritizing PLHIV for COVID-19 vaccination. Data on immune responses after messenger RNA (mRNA) vaccination in PLHIV in relation to CD4 counts are scarce. We aimed at assessing the humoral immune response in PLHIV after mRNA vaccination against COVID-19. We examined a cohort of PLHIV after prime (n = 88) and boost (n = 52) vaccination with BNT162b2. We assessed levels of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein-specific immunoglobulin G (IgG)/IgA and circulating neutralizing antibodies in plasma and correlated results to the cellular immune status. BNT162b2-vaccinated health care workers served as controls. All PLWH had a viral load of ≤ 200 HIV-1 RNA copies/mL and 96.5% had a viral load of < 50 copies/mL. Anti-S IgG and neutralizing antibody responses after BNT162b2 priming were significantly lower in PLHIV having a CD4:CD8 T-cell ratio of < 0.5. However, we observed robust humoral immunity in the majority of PLWH receiving antiretroviral therapy (ART) irrespective of CD4 T-cell nadir, current CD4 count or CD4:CD8 ratio after full BNT162b2 vaccination. Nevertheless, HIV-negative controls produced significantly higher mean anti-S IgG concentrations with less variability. The majority of PLWH mounted robust responses after complete BNT162b2 vaccination but overall amounts of antibodies directed against the SARS-CoV-2 receptor-binding domain were variable. The impact on clinical efficacy remains unclear.

Jedicke N ，Stankov MV ，Cossmann A ，Dopfer-Jablonka A ，Knuth C ，Ahrenstorf G ，Ramos GM ，Behrens GMN ... -  《-》

Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Co

Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count. PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm3; intermediate CD4 recovery, ICDR: 200-500/mm3; high CD4 recovery, HCDR: >500/mm3). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used. Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters. Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm3 versus those with >500 cell/mm3 and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200-500/mm3, whereas immune response elicited in PLWH with a CD4 T-cell >500/mm3 was comparable to HIV-negative population.

Antinori A ，Cicalini S ，Meschi S ，Bordoni V ，Lorenzini P ，Vergori A ，Lanini S ，De Pascale L ，Matusali G ，Mariotti D ，Cozzi Lepri A ，Gallì P ，Pinnetti C ，Gagliardini R ，Mazzotta V ，Mastrorosa I ，Grisetti S ，Colavita F ，Cimini E ，Grilli E ，Bellagamba R ，Lapa D ，Sacchi A ，Marani A ，Cerini C ，Candela C ，Fusto M ，Puro V ，Castilletti C ，Agrati C ，Girardi E ，Vaia F ，HIV-VAC Study Group ... -  《-》

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.

Hensley KS ，Jongkees MJ ，Geers D ，GeurtsvanKessel CH ，Mueller YM ，Dalm VASH ，Papageorgiou G ，Steggink H ，Gorska A ，Bogers S ，den Hollander JG ，Bierman WFW ，Gelinck LBS ，Schippers EF ，Ammerlaan HSM ，van der Valk M ，van Vonderen MGA ，Delsing CE ，Gisolf EH ，Bruns AHW ，Lauw FN ，Berrevoets MAH ，Sigaloff KCE ，Soetekouw R ，Branger J ，de Mast Q ，Lammers AJJ ，Lowe SH ，de Vries RD ，Katsikis PD ，Rijnders BJA ，Brinkman K ，Roukens AHE ，Rokx C ... -  《-》

Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.

Wolff M ，Charpentier P ，Canals A ，Vial C ，Hormazábal J ，Cortés J ，Silva M ... -  《-》

Humoral and Cellular Immune Response Elicited by Two Doses of mRNA BNT162b2 Vaccine Against SARS-CoV-2 in People Living with HIV.

Vanetti C ，Milazzo L ，Ardizzone F ，Oreni L ，Cappelletti G ，Trabattoni D ，Biasin M ... -  《-》